NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

Browse trials for

• Dry Eye Syndromes 1,325

Keywords

• Dry Eye
• Cyclosporine

Dry Eye Syndromes

1,325 studies on the registry are indexed under Dry Eye Syndromes; 193 are open to participants now.

This study's enrollment of 132 is above the median of 60 across 1,103 interventional studies indexed under Dry Eye Syndromes.

Lead sponsor

Santen SAS is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

First submitted before Santen Inc. became part of Santen Pharmaceutical Co., Ltd..

Study arms

• Experimental
  1

  Cyclosporine 0.05%

  Drug: NOVA22007 ''Cyclosporine''

• Experimental
  2

  Cyclosporine 0.1%

  Drug: NOVA22007 ''Cyclosporine''

• Placebo comparator
  3

  vehicle/placebo

  Drug: vehicle/placebo

Interventions

• DrugNOVA22007 ''Cyclosporine''

  Cyclosporine 0.05% Ophthalmic Cationic Emulsions

• DrugNOVA22007 ''Cyclosporine''

  Cyclosporine 0.1% Ophthalmic Cationic Emulsions

• Drugvehicle/placebo

  vehicle/placebo

Primary outcomes

1. Assess the safety and efficacy of two doses of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Emulsions

   Time frame: Approximately 13 weeks